PACIFIC BIOSCIENCES OF CALIF
PACBNASDAQ🏆 #3044 by market capEarnings Nov 3 · PostUS Equity
$1.10▼ $0.04 (−3.95%)
Live1h▲ 0.0%
24h▼ 4.0%
7d▼ 15.4%
14d▼ 22.3%
30d▼ 27.0%
1y▼ 8.8%
🏦Market Cap
$340M
Small Cap
📈Revenue Growth (YoY)
+3.9%
Slowing
📊Gross Margin
36.0%
Healthy
💵FCF Margin
-107.5%
Thin
⚖️P/S Ratio
2.2x
Cheap
Otter Score
56
Weak
📊
Analyst Ratings
Price
$1.10
Total
18
Raised
2
Lowered
4
Avg PT
$1.00
H / L
$1 / $1
| Institution | Action | Rating | Date |
|---|---|---|---|
Barclays | Reiterated | Underweight | 2026-05-11 |
Piper Sandler | Reiterated | Neutral | 2025-11-11 |
Stephens & Co. | Reiterated | Overweight | 2025-11-10 |
Canaccord Genuity | Reiterated | Buy | 2025-04-10 |
Scotiabank | Reiterated | Sector Outperform | 2025-03-25 |
Goldman Sachs | Reiterated | Neutral | 2025-02-18 |
UBS | Downgraded | Buy → Neutral | 2024-11-11 |
Morgan Stanley | Reiterated | Equal Weight | 2024-08-12 |
Cantor Fitzgerald | Reiterated | Overweight | 2024-08-08 |
JP Morgan | Downgraded | Overweight → Neutral | 2024-04-22 |
Bernstein | Reiterated | Outperform | 2024-04-18 |
TD Cowen | Reiterated | Buy | 2024-04-17 |
Piper Jaffray | Upgraded | Neutral → Overweight | 2019-10-15 |
Cowen & Co. | Downgraded | Outperform → Market Perform | 2019-01-04 |
MKM Partners | Reiterated | Neutral | 2016-04-15 |
First Analysis | Reiterated | Overweight | 2016-04-15 |
PiperJaffray | Downgraded | Overweight → Neutral | 2016-02-04 |
William Blair | Upgraded | Market Perform → Outperform | 2015-05-01 |
One row per institution, most recent rating